Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection

S. L. Rhodes, H. Erlich, K. A. Im, J. Wang, J. Li, T. Bugawan, Lennox J Jeffers, X. Tong, X. Su, H. R. Rosen, L. J. Yee, T. J. Liang, H. Yang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The human major histocompatability complex (MHC) genes encode the human leukocyte antigens, which are important in antigen presentation and regulation of CD8+ and CD4+ T cells. Response to therapies in hepatitis C virus (HCV) infection is highly variable (30-80%) and lower response rates have been reported among African Americans (AA; ∼30%) compared to Caucasian Americans (CA; ∼50%) infected with genotype-1 viruses. We evaluated whether MHC gene variants were associated with response to therapy and racial differences in AA and CA sustained virologic response (SVR) rates. We genotyped alleles at 8 MHC loci: 3 class I (A, B and C) and 5 class II (DRB1, DQA1, DQB1, DPA1 and DPB1) loci in 373 individuals (179 AA and 194 CA) with genotype-1 HCV infections, who were treated with peginterferon-α-2a and ribavirin. We observed carriage of A*02 (RR=1.33(1.08-1.64); P=0.008), B*58 (RR=1.84(1.24-2.73); P=0.002) and DPB1*1701 (RR=1.57(1.09-2.26); P=0.015) to be associated with SVR after adjustment for other predictors of response. In analysis of AA and CA subgroups separately, we observed potential, though not statistically significant, differences in these MHC associations. Variation in the immunogenetic background of HCV-infected individuals might account for some observed variation in viral-specific immunity and courses of disease. In this regard, future studies examining broader patient populations are warranted.

Original languageEnglish
Pages (from-to)328-333
Number of pages6
JournalGenes and Immunity
Volume9
Issue number4
DOIs
StatePublished - Jun 1 2008

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Genotype
Immunogenetics
Ribavirin
Antigen Presentation
HLA Antigens
African Americans
Genes
Immunity
Therapeutics
Alleles
Viruses
T-Lymphocytes
Population
Sustained Virologic Response

ASJC Scopus subject areas

  • Genetics(clinical)
  • Immunology
  • Genetics

Cite this

Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. / Rhodes, S. L.; Erlich, H.; Im, K. A.; Wang, J.; Li, J.; Bugawan, T.; Jeffers, Lennox J; Tong, X.; Su, X.; Rosen, H. R.; Yee, L. J.; Liang, T. J.; Yang, H.

In: Genes and Immunity, Vol. 9, No. 4, 01.06.2008, p. 328-333.

Research output: Contribution to journalArticle

Rhodes, SL, Erlich, H, Im, KA, Wang, J, Li, J, Bugawan, T, Jeffers, LJ, Tong, X, Su, X, Rosen, HR, Yee, LJ, Liang, TJ & Yang, H 2008, 'Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection', Genes and Immunity, vol. 9, no. 4, pp. 328-333. https://doi.org/10.1038/gene.2008.21
Rhodes, S. L. ; Erlich, H. ; Im, K. A. ; Wang, J. ; Li, J. ; Bugawan, T. ; Jeffers, Lennox J ; Tong, X. ; Su, X. ; Rosen, H. R. ; Yee, L. J. ; Liang, T. J. ; Yang, H. / Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. In: Genes and Immunity. 2008 ; Vol. 9, No. 4. pp. 328-333.
@article{c6bb036b544e492488714a1493e44aaf,
title = "Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection",
abstract = "The human major histocompatability complex (MHC) genes encode the human leukocyte antigens, which are important in antigen presentation and regulation of CD8+ and CD4+ T cells. Response to therapies in hepatitis C virus (HCV) infection is highly variable (30-80{\%}) and lower response rates have been reported among African Americans (AA; ∼30{\%}) compared to Caucasian Americans (CA; ∼50{\%}) infected with genotype-1 viruses. We evaluated whether MHC gene variants were associated with response to therapy and racial differences in AA and CA sustained virologic response (SVR) rates. We genotyped alleles at 8 MHC loci: 3 class I (A, B and C) and 5 class II (DRB1, DQA1, DQB1, DPA1 and DPB1) loci in 373 individuals (179 AA and 194 CA) with genotype-1 HCV infections, who were treated with peginterferon-α-2a and ribavirin. We observed carriage of A*02 (RR=1.33(1.08-1.64); P=0.008), B*58 (RR=1.84(1.24-2.73); P=0.002) and DPB1*1701 (RR=1.57(1.09-2.26); P=0.015) to be associated with SVR after adjustment for other predictors of response. In analysis of AA and CA subgroups separately, we observed potential, though not statistically significant, differences in these MHC associations. Variation in the immunogenetic background of HCV-infected individuals might account for some observed variation in viral-specific immunity and courses of disease. In this regard, future studies examining broader patient populations are warranted.",
author = "Rhodes, {S. L.} and H. Erlich and Im, {K. A.} and J. Wang and J. Li and T. Bugawan and Jeffers, {Lennox J} and X. Tong and X. Su and Rosen, {H. R.} and Yee, {L. J.} and Liang, {T. J.} and H. Yang",
year = "2008",
month = "6",
day = "1",
doi = "10.1038/gene.2008.21",
language = "English",
volume = "9",
pages = "328--333",
journal = "Genes and Immunity",
issn = "1466-4879",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection

AU - Rhodes, S. L.

AU - Erlich, H.

AU - Im, K. A.

AU - Wang, J.

AU - Li, J.

AU - Bugawan, T.

AU - Jeffers, Lennox J

AU - Tong, X.

AU - Su, X.

AU - Rosen, H. R.

AU - Yee, L. J.

AU - Liang, T. J.

AU - Yang, H.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - The human major histocompatability complex (MHC) genes encode the human leukocyte antigens, which are important in antigen presentation and regulation of CD8+ and CD4+ T cells. Response to therapies in hepatitis C virus (HCV) infection is highly variable (30-80%) and lower response rates have been reported among African Americans (AA; ∼30%) compared to Caucasian Americans (CA; ∼50%) infected with genotype-1 viruses. We evaluated whether MHC gene variants were associated with response to therapy and racial differences in AA and CA sustained virologic response (SVR) rates. We genotyped alleles at 8 MHC loci: 3 class I (A, B and C) and 5 class II (DRB1, DQA1, DQB1, DPA1 and DPB1) loci in 373 individuals (179 AA and 194 CA) with genotype-1 HCV infections, who were treated with peginterferon-α-2a and ribavirin. We observed carriage of A*02 (RR=1.33(1.08-1.64); P=0.008), B*58 (RR=1.84(1.24-2.73); P=0.002) and DPB1*1701 (RR=1.57(1.09-2.26); P=0.015) to be associated with SVR after adjustment for other predictors of response. In analysis of AA and CA subgroups separately, we observed potential, though not statistically significant, differences in these MHC associations. Variation in the immunogenetic background of HCV-infected individuals might account for some observed variation in viral-specific immunity and courses of disease. In this regard, future studies examining broader patient populations are warranted.

AB - The human major histocompatability complex (MHC) genes encode the human leukocyte antigens, which are important in antigen presentation and regulation of CD8+ and CD4+ T cells. Response to therapies in hepatitis C virus (HCV) infection is highly variable (30-80%) and lower response rates have been reported among African Americans (AA; ∼30%) compared to Caucasian Americans (CA; ∼50%) infected with genotype-1 viruses. We evaluated whether MHC gene variants were associated with response to therapy and racial differences in AA and CA sustained virologic response (SVR) rates. We genotyped alleles at 8 MHC loci: 3 class I (A, B and C) and 5 class II (DRB1, DQA1, DQB1, DPA1 and DPB1) loci in 373 individuals (179 AA and 194 CA) with genotype-1 HCV infections, who were treated with peginterferon-α-2a and ribavirin. We observed carriage of A*02 (RR=1.33(1.08-1.64); P=0.008), B*58 (RR=1.84(1.24-2.73); P=0.002) and DPB1*1701 (RR=1.57(1.09-2.26); P=0.015) to be associated with SVR after adjustment for other predictors of response. In analysis of AA and CA subgroups separately, we observed potential, though not statistically significant, differences in these MHC associations. Variation in the immunogenetic background of HCV-infected individuals might account for some observed variation in viral-specific immunity and courses of disease. In this regard, future studies examining broader patient populations are warranted.

UR - http://www.scopus.com/inward/record.url?scp=44849095839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849095839&partnerID=8YFLogxK

U2 - 10.1038/gene.2008.21

DO - 10.1038/gene.2008.21

M3 - Article

VL - 9

SP - 328

EP - 333

JO - Genes and Immunity

JF - Genes and Immunity

SN - 1466-4879

IS - 4

ER -